Document Detail


iRHOM2 takes control of rheumatoid arthritis.
MedLine Citation:
PMID:  23348732     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The cytokine TNF-α is a major drug target for rheumatoid arthritis, an inflammatory joint disorder. An alternative approach is to target the protease TNF-α convertase (TACE), which releases TNF-α from cells. However, because TACE cleaves other proteins involved in development and cancer, a tissue-specific inhibition of TACE in immune cells appears mandatory. In this issue of the JCI, Issuree et al. report that iRHOM2 is a TACE activator in immune cells. Loss of iRHOM2 largely protects mice from inflammatory arthritis, making iRHOM2 a potential drug target for this condition.
Authors:
Stefan F Lichtenthaler
Publication Detail:
Type:  Comment; Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-01-25
Journal Detail:
Title:  The Journal of clinical investigation     Volume:  123     ISSN:  1558-8238     ISO Abbreviation:  J. Clin. Invest.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-04-19     Completed Date:  2013-05-13     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  7802877     Medline TA:  J Clin Invest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  560-2     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Arthritis, Experimental / etiology*
Carrier Proteins / physiology*
Humans
Chemical
Reg. No./Substance:
0/Carrier Proteins; 0/iRhom2 protein, mouse
Comments/Corrections
Comment On:
J Clin Invest. 2013 Feb 1;123(2):928-32   [PMID:  23348744 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ubiquitylation and the pathogenesis of hypertension.
Next Document:  Old King coal - molecular mechanisms underlying an ancient treatment for atopic eczema.